Latest Bowel Cancer News

An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Rhythm Biosciences marked its transition to commercialisation with first sales of ColoSTAT® and geneType™ tests, despite a 55% increase in loss to $5.93 million. The company expanded market access and secured manufacturing agreements, while NHS England began evaluating ColoSTAT® for bowel cancer screening.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.